Modality
Cell Therapy
MOA
FXIai
Target
B7-H3
Pathway
mTOR
Parkinson's
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
~Jan 2019
→ ~Apr 2020
Phase 3
Jul 2020
→ Jan 2031
Phase 3Current
NCT08282505
860 pts·Parkinson's
2020-07→2030-06·Terminated
NCT05471654
2,942 pts·Parkinson's
2024-07→2031-01·Terminated
NCT07492847
1,327 pts·Parkinson's
2024-03→2030-09·Recruiting
+1 more trial
6,660 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2029-10-133.5y awayPh3 Readout· Parkinson's
2030-06-114.2y awayPh3 Readout· Parkinson's
2030-09-044.4y awayPh3 Readout· Parkinson's
2031-01-014.8y awayPh3 Readout· Parkinson's
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P3
Termina…
P3
Recruit…
P3
Termina…
P3
Recruit…
Catalysts
Ph3 Readout
2029-10-13 · 3.5y away
Parkinson's
Ph3 Readout
2030-06-11 · 4.2y away
Parkinson's
Ph3 Readout
2030-09-04 · 4.4y away
Parkinson's
Ph3 Readout
2031-01-01 · 4.8y away
Parkinson's
RecruitingTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08282505 | Phase 3 | Parkinson's | Terminated | 860 | MRD |
| NCT05471654 | Phase 3 | Parkinson's | Terminated | 2942 | CfB |
| NCT07492847 | Phase 3 | Parkinson's | Recruiting | 1327 | SRI-4 |
| NCT07530717 | Phase 3 | Parkinson's | Recruiting | 1531 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |